BioTime, Inc. (BTX) Announces Four Human Embryonic Stem Cell Lines Approved for Inclusion in NIH Registry
BioTime, Inc., a California biotechnology company focused on regenerative medicine and blood plasma volume expanders, today announced NIH (National Institutes of Health) approval of four of the company’s embryonic stem cell lines for inclusion in the NIH Human Embryonic Stem Cell Registry. The four stem cell lines are ESI-035, ESI-049, ESI-051, and ESI-053, developed by BioTime wholly owned subsidiary ES Cell International (ESI), one of the earliest pioneers of human embryonic stem cell technology BioTime President and CEO, Michael D. West, Ph.D., commented on the announcement. “As researchers work towards developing therapeutics for use in hard-to-treat diseases, we believe that…